KR20250002720A - 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 - Google Patents

가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 Download PDF

Info

Publication number
KR20250002720A
KR20250002720A KR1020247039985A KR20247039985A KR20250002720A KR 20250002720 A KR20250002720 A KR 20250002720A KR 1020247039985 A KR1020247039985 A KR 1020247039985A KR 20247039985 A KR20247039985 A KR 20247039985A KR 20250002720 A KR20250002720 A KR 20250002720A
Authority
KR
South Korea
Prior art keywords
compound
chemical formula
formula
base
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039985A
Other languages
English (en)
Korean (ko)
Inventor
데브라 제인 월러스
펭거 조우
유광 왕
다카시 나카이
비쉬누 바드한 레디 카나티
웨이니 씨. 쉐어러
윌리엄 키슬
송 수에
아마드 하샤쉬
Original Assignee
사이클리온 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by 사이클리온 테라퓨틱스, 인크. filed Critical 사이클리온 테라퓨틱스, 인크.
Priority to KR1020257010603A priority Critical patent/KR20250048609A/ko
Publication of KR20250002720A publication Critical patent/KR20250002720A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247039985A 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 Pending KR20250002720A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257010603A KR20250048609A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
US62/615,678 2018-01-10
CNPCT/CN2018/076982 2018-02-22
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
PCT/US2019/013060 WO2019140095A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
KR1020207022640A KR102739727B1 (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207022640A Division KR102739727B1 (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257010603A Division KR20250048609A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Publications (1)

Publication Number Publication Date
KR20250002720A true KR20250002720A (ko) 2025-01-07

Family

ID=65279655

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247039985A Pending KR20250002720A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체
KR1020257010603A Pending KR20250048609A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체
KR1020207022640A Active KR102739727B1 (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257010603A Pending KR20250048609A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체
KR1020207022640A Active KR102739727B1 (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체

Country Status (17)

Country Link
US (5) US11274096B2 (https=)
EP (3) EP4570797A3 (https=)
JP (2) JP7357621B2 (https=)
KR (3) KR20250002720A (https=)
CN (3) CN118184645A (https=)
AU (3) AU2019206560B2 (https=)
BR (1) BR112020013985A2 (https=)
CA (1) CA3087943A1 (https=)
CL (3) CL2020001814A1 (https=)
ES (1) ES2963447T3 (https=)
IL (3) IL314714A (https=)
JO (1) JOP20200165A1 (https=)
MA (2) MA71753A (https=)
MX (3) MX2020007364A (https=)
SG (1) SG11202006311SA (https=)
TW (2) TWI888947B (https=)
WO (1) WO2019140095A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588465B1 (en) * 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EA033168B1 (ru) * 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
EA201790627A1 (ru) * 2014-09-17 2017-09-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
CA3006746C (en) 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
CN109563086B (zh) 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Also Published As

Publication number Publication date
EP3737679C0 (en) 2023-09-06
US11274096B2 (en) 2022-03-15
SG11202006311SA (en) 2020-07-29
KR20200106920A (ko) 2020-09-15
AU2025202281A9 (en) 2025-05-15
AU2023270260B2 (en) 2026-01-29
AU2019206560B2 (en) 2023-08-24
US11708361B2 (en) 2023-07-25
MX2020007364A (es) 2020-11-18
US20220024909A1 (en) 2022-01-27
US12030874B2 (en) 2024-07-09
WO2019140095A8 (en) 2020-06-18
JP2021511299A (ja) 2021-05-06
IL319883A (en) 2025-05-01
CL2022000907A1 (es) 2022-10-21
JOP20200165A1 (ar) 2022-10-30
ES2963447T3 (es) 2024-03-27
IL314714A (en) 2024-10-01
EP4570797A2 (en) 2025-06-18
IL275748B1 (en) 2024-09-01
EP4570797A3 (en) 2025-09-03
IL275748A (en) 2020-08-31
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
US20210053962A1 (en) 2021-02-25
IL275748B2 (en) 2025-01-01
JP2023182647A (ja) 2023-12-26
AU2025202281A1 (en) 2025-04-17
CA3087943A1 (en) 2019-07-18
MA51565A (fr) 2020-11-18
TW202402741A (zh) 2024-01-16
KR102739727B1 (ko) 2024-12-05
CN111902410B (zh) 2024-04-19
MA71753A (fr) 2025-05-30
US20240391911A1 (en) 2024-11-28
AU2023270260A1 (en) 2023-12-07
US20230339928A1 (en) 2023-10-26
TWI821237B (zh) 2023-11-11
CN111902410A (zh) 2020-11-06
EP4249469A2 (en) 2023-09-27
EP3737679B1 (en) 2023-09-06
MX2023000045A (es) 2023-02-01
JP7357621B2 (ja) 2023-10-06
JP7744955B2 (ja) 2025-09-26
CL2020001814A1 (es) 2020-11-06
EP4249469A3 (en) 2023-12-27
TWI888947B (zh) 2025-07-01
CN118221665A (zh) 2024-06-21
WO2019140095A1 (en) 2019-07-18
AU2019206560A1 (en) 2020-07-30
US12275724B2 (en) 2025-04-15
EP3737679A1 (en) 2020-11-18
US20250361228A1 (en) 2025-11-27
BR112020013985A2 (pt) 2020-12-01
CN118184645A (zh) 2024-06-14
CL2022000904A1 (es) 2022-10-21
MX2023000044A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
JP7744955B2 (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
EP3915977A1 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
HK40103207A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK40031722A (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
HK40031722B (en) Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
EA045335B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
EA048211B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
EA052114B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
WO2019161534A1 (en) Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241202

Application number text: 1020207022640

Filing date: 20200805

PA0201 Request for examination
PG1501 Laying open of application
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250401

Application number text: 1020207022640

Filing date: 20200805